- Micromem Technologies Inc. reported a **shareholders' deficiency of $(6,239,142)** and a **working capital deficiency of $6,214,473** as of July 31, 2025, with **negative cash flow from operations of $(829,494)** for the nine months ended July 31, 2025.  **[1085921_0001062993-25-015828_exhibit99-1.htm:0]** **[1085921_0001062993-25-015828_exhibit99-1.htm:3]** **[1085921_0001062993-25-015828_exhibit99-2.htm:6]** 
- The company is developing **cutting-edge biochemical sensors** through a collaboration with the **University of Toronto, DRDC, and NSERC**, securing **exclusive worldwide license** to the intellectual property.  **[1085921_0001062993-25-015828_exhibit99-2.htm:0]** **[1085921_0001062993-25-015828_exhibit99-2.htm:2]** **[1085921_0001062993-25-015828_exhibit99-2.htm:3]**  This new technology is replacing the previously pursued ARTRA technology.  **[1085921_0001062993-25-015828_exhibit99-2.htm:0]** **[1085921_0001062993-25-015828_exhibit99-2.htm:5]** 
- Micromem is engaged in ongoing discussions with **Chevron** and pursuing business opportunities with **Romgaz** and other energy companies in Romania.  **[1085921_0001062993-25-015828_exhibit99-2.htm:0]** **[1085921_0001062993-25-015828_exhibit99-2.htm:2]** **[1085921_0001062993-25-015828_exhibit99-2.htm:5]** 
- During Q3 2025, the company secured **$389,937** from private placements and **$40,000** from convertible debenture issuances.  **[1085921_0001062993-25-015828_exhibit99-2.htm:5]**  It also continues to receive monthly payments from a lawsuit settlement through September 2027.  **[1085921_0001062993-25-015828_exhibit99-2.htm:3]** **[1085921_0001062993-25-015828_exhibit99-2.htm:10]**

MICROMEM TECHNOLOGIES (MMTIF)